Using 2-DE, a change (decrease) in RBP4 was also observed in the group of chemosensitive patients with multiple myeloma, which were treated with bortezomib-based regimens, when compared with patients resistant to chemotherapy [36], and also in the sera of epithelial ovarian cancer patients [37]. Here, RBP4 is linked to plasma cell myeloma.